^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Microtubule inhibitor

    Related drugs:
    1d
    JK06.1.01: Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1/2, N=255, Recruiting, Salubris Biotherapeutics Inc | N=155 --> 255
    Enrollment change • First-in-human
    1d
    BV-ALLO: Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=14, Completed, University of Cologne | Recruiting --> Completed | N=21 --> 14
    Trial completion • Enrollment change
    |
    Adcetris (brentuximab vedotin)
    1d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Completed --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    1d
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    2d
    A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)
    P1, N=121, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • paclitaxel • pemetrexed • Aidixi (disitamab vedotin)
    2d
    A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • RET fusion • ALK fusion • ALK mutation • RET mutation • ROS1 fusion • EGFR positive • NTRK fusion
    |
    Avastin (bevacizumab) • etoposide IV • utidelone IV (UTD1)
    3d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Completed, PETHEMA Foundation | Not yet recruiting --> Completed
    Trial completion
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)
    3d
    IgA Vasculitis Developing during Trastuzumab Emtansine Therapy for HER2-positive Breast Cancer. (PubMed, Intern Med)
    Owing to active renal lesions, the patient was treated with prednisolone and cyclophosphamide, which resulted in clinical remission. This case was considered to have T-DM1-associated IgA vasculitis. Although rare, an awareness of the possibility of serious adverse effects associated with drug administration is important.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Kadcyla (ado-trastuzumab emtansine) • cyclophosphamide
    3d
    Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers (clinicaltrials.gov)
    P2, N=131, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 amplification
    |
    MSK-IMPACT
    |
    Kadcyla (ado-trastuzumab emtansine)
    4d
    A Study of PLB-002 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=100, Recruiting, Primelink BioTherapeitics(ShenZhen) Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CLDN6 (Claudin 6)
    4d
    Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study (clinicaltrials.gov)
    P2, N=37, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Aidixi (disitamab vedotin)
    5d
    A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Hu Hai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • HER-2 negative + HR negative
    |
    Halaven (eribulin mesylate) • Itovebi (inavolisib)